Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: A randomized, double-blind, placebo-controlled, dose-ranging study

D. E. Kellstein, Richard B. Lipton, R. Geetha, K. Koronkiewicz, F. T. Evans, W. F. Stewart, K. Wilkes, S. A. Furey, T. Subramanian, S. A. Cooper

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

A total of 729 migraine sufferers with moderate to severe baseline pain evaluated a single 200, 400 or 600 mg dose of a new liquigel formulation of ibuprofen over 8 h. Ibuprofen liquigels were significantly superior to placebo for cumulative headache response (pain reduced to mild or none) from 0.5 (600 mg) or 1 h (200 and 400 mg) to 8 h. At 2 h, respective headache response rates for ibuprofen 200, 400 and 600 mg and placebo were 64%, 72%, 72% and 50%. All three doses were also significantly superior to placebo for 2-h pain-free (25%, 28%, 29% and 13%, respectively) and for proportions with mild or no limitation of activity (2-8 h). Ibuprofen liquigels were generally superior to placebo for reducing photophobia, phonophobia, or nausea (1-4 h) and for global evaluation. All doses were well tolerated. These data demonstrate that ibuprofen liquigels relieve the pain, ancillary symptoms, and limitation of activity, of migraine.

Original languageEnglish (US)
Pages (from-to)233-243
Number of pages11
JournalCephalalgia
Volume20
Issue number4
DOIs
StatePublished - 2000

Fingerprint

Ibuprofen
Migraine Disorders
Placebos
Pain
Headache
Hyperacusis
Therapeutics
Photophobia
Nausea

Keywords

  • Ibuprofen
  • Liquigel
  • Migraine
  • Nonprescription
  • NSAID

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache : A randomized, double-blind, placebo-controlled, dose-ranging study. / Kellstein, D. E.; Lipton, Richard B.; Geetha, R.; Koronkiewicz, K.; Evans, F. T.; Stewart, W. F.; Wilkes, K.; Furey, S. A.; Subramanian, T.; Cooper, S. A.

In: Cephalalgia, Vol. 20, No. 4, 2000, p. 233-243.

Research output: Contribution to journalArticle

Kellstein, DE, Lipton, RB, Geetha, R, Koronkiewicz, K, Evans, FT, Stewart, WF, Wilkes, K, Furey, SA, Subramanian, T & Cooper, SA 2000, 'Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: A randomized, double-blind, placebo-controlled, dose-ranging study', Cephalalgia, vol. 20, no. 4, pp. 233-243. https://doi.org/10.1046/j.1468-2982.2000.00055.x
Kellstein, D. E. ; Lipton, Richard B. ; Geetha, R. ; Koronkiewicz, K. ; Evans, F. T. ; Stewart, W. F. ; Wilkes, K. ; Furey, S. A. ; Subramanian, T. ; Cooper, S. A. / Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache : A randomized, double-blind, placebo-controlled, dose-ranging study. In: Cephalalgia. 2000 ; Vol. 20, No. 4. pp. 233-243.
@article{90f88f24629048b78f34d7e920bb9c57,
title = "Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: A randomized, double-blind, placebo-controlled, dose-ranging study",
abstract = "A total of 729 migraine sufferers with moderate to severe baseline pain evaluated a single 200, 400 or 600 mg dose of a new liquigel formulation of ibuprofen over 8 h. Ibuprofen liquigels were significantly superior to placebo for cumulative headache response (pain reduced to mild or none) from 0.5 (600 mg) or 1 h (200 and 400 mg) to 8 h. At 2 h, respective headache response rates for ibuprofen 200, 400 and 600 mg and placebo were 64{\%}, 72{\%}, 72{\%} and 50{\%}. All three doses were also significantly superior to placebo for 2-h pain-free (25{\%}, 28{\%}, 29{\%} and 13{\%}, respectively) and for proportions with mild or no limitation of activity (2-8 h). Ibuprofen liquigels were generally superior to placebo for reducing photophobia, phonophobia, or nausea (1-4 h) and for global evaluation. All doses were well tolerated. These data demonstrate that ibuprofen liquigels relieve the pain, ancillary symptoms, and limitation of activity, of migraine.",
keywords = "Ibuprofen, Liquigel, Migraine, Nonprescription, NSAID",
author = "Kellstein, {D. E.} and Lipton, {Richard B.} and R. Geetha and K. Koronkiewicz and Evans, {F. T.} and Stewart, {W. F.} and K. Wilkes and Furey, {S. A.} and T. Subramanian and Cooper, {S. A.}",
year = "2000",
doi = "10.1046/j.1468-2982.2000.00055.x",
language = "English (US)",
volume = "20",
pages = "233--243",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache

T2 - A randomized, double-blind, placebo-controlled, dose-ranging study

AU - Kellstein, D. E.

AU - Lipton, Richard B.

AU - Geetha, R.

AU - Koronkiewicz, K.

AU - Evans, F. T.

AU - Stewart, W. F.

AU - Wilkes, K.

AU - Furey, S. A.

AU - Subramanian, T.

AU - Cooper, S. A.

PY - 2000

Y1 - 2000

N2 - A total of 729 migraine sufferers with moderate to severe baseline pain evaluated a single 200, 400 or 600 mg dose of a new liquigel formulation of ibuprofen over 8 h. Ibuprofen liquigels were significantly superior to placebo for cumulative headache response (pain reduced to mild or none) from 0.5 (600 mg) or 1 h (200 and 400 mg) to 8 h. At 2 h, respective headache response rates for ibuprofen 200, 400 and 600 mg and placebo were 64%, 72%, 72% and 50%. All three doses were also significantly superior to placebo for 2-h pain-free (25%, 28%, 29% and 13%, respectively) and for proportions with mild or no limitation of activity (2-8 h). Ibuprofen liquigels were generally superior to placebo for reducing photophobia, phonophobia, or nausea (1-4 h) and for global evaluation. All doses were well tolerated. These data demonstrate that ibuprofen liquigels relieve the pain, ancillary symptoms, and limitation of activity, of migraine.

AB - A total of 729 migraine sufferers with moderate to severe baseline pain evaluated a single 200, 400 or 600 mg dose of a new liquigel formulation of ibuprofen over 8 h. Ibuprofen liquigels were significantly superior to placebo for cumulative headache response (pain reduced to mild or none) from 0.5 (600 mg) or 1 h (200 and 400 mg) to 8 h. At 2 h, respective headache response rates for ibuprofen 200, 400 and 600 mg and placebo were 64%, 72%, 72% and 50%. All three doses were also significantly superior to placebo for 2-h pain-free (25%, 28%, 29% and 13%, respectively) and for proportions with mild or no limitation of activity (2-8 h). Ibuprofen liquigels were generally superior to placebo for reducing photophobia, phonophobia, or nausea (1-4 h) and for global evaluation. All doses were well tolerated. These data demonstrate that ibuprofen liquigels relieve the pain, ancillary symptoms, and limitation of activity, of migraine.

KW - Ibuprofen

KW - Liquigel

KW - Migraine

KW - Nonprescription

KW - NSAID

UR - http://www.scopus.com/inward/record.url?scp=0034453791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034453791&partnerID=8YFLogxK

U2 - 10.1046/j.1468-2982.2000.00055.x

DO - 10.1046/j.1468-2982.2000.00055.x

M3 - Article

C2 - 10999673

AN - SCOPUS:0034453791

VL - 20

SP - 233

EP - 243

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 4

ER -